• 64Cu-SAR-bisPSMA identified 2.6x more lesions per patient than 68Ga-PSMA-11
• 64Cu-SAR-bisPSMA detected prostate cancer in 78% of patients vs. 36% for 68Ga-PSMA-11
• Planned patient management changed in 44% of cases after 64Cu-SAR-bisPSMA assessment

Clarity Pharmaceuticals announced the release of an abstract on the Co-PSMA Investigator-Initiated Trial, which evaluated the performance of its diagnostic product, 64Cu-SAR-bisPSMA, in a head-to-head comparison to standard-of-care 68Ga-PSMA-11 in 50 prostate cancer patients with biochemical recurrence. The study, led by Prof Louise Emmett at St Vincent's Hospital Sydney, found that 64Cu-SAR-bisPSMA PET/CT identified a statistically significant greater number of lesions per participant than 68Ga-PSMA-11 PET/CT, with a mean of 1.26 lesions per patient compared to 0.48 for 68Ga-PSMA-11. In total, 68Ga-PSMA-11 identified 24 lesions across all participants, while 64Cu-SAR-bisPSMA next-day imaging detected 63 lesions. At the per-patient level, 64Cu-SAR-bisPSMA detected prostate cancer in 78% of cases, compared to 36% for 68Ga-PSMA-11. Planned patient management changed following the assessment of 64Cu-SAR-bisPSMA scans in 44% of trial participants. These results build on the growing body of evidence showing that 64Cu-SAR-bisPSMA improves the detection of prostate cancer compared to current standard-of-care PSMA PET agents.

Clarity believes 64Cu-SAR-bisPSMA could become the new standard-of-care in PSMA PET imaging and substantially improve the diagnosis of prostate cancer in many stages of the disease, from early phases pre-definitive therapy to better identification of lesions in biochemical recurrence, including in patients with oligometastatic disease.